RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts

Area of Science:

• Cardiovascular pharmacology
• Lipid metabolism
• RNA interference therapeutics

Background:

• Elevated triglycerides and non-high-density lipoprotein cholesterol (HDL-C) are key risk factors for atherosclerotic cardiovascular disease (ASCVD).
• Angiopoietin-like protein 3 (ANGPTL3) plays a crucial role in regulating lipoprotein metabolism.
• Targeting ANGPTL3 presents a potential therapeutic strategy for managing dyslipidemia and reducing ASCVD risk.

Purpose of the Study:

• To evaluate the safety, pharmacokinetics, and pharmacodynamics of ARO-ANG3, an RNA interference therapy targeting ANGPTL3.
• To assess the impact of single and repeat doses of ARO-ANG3 on ANGPTL3, triglyceride, and non-HDL-C levels in healthy participants and those with hepatic steatosis.

Main Methods:

• A first-in-human, phase 1, randomized, placebo-controlled, open-label trial involving healthy participants and participants with hepatic steatosis.
• Administration of single and repeat doses of ARO-ANG3 across multiple cohorts.
• Evaluation of safety, systemic absorption, and ANGPTL3, triglyceride, and non-HDL-C levels post-dosing.

Main Results:

• ARO-ANG3 was generally well tolerated with comparable adverse event rates between active and placebo groups.
• Rapid and sustained systemic absorption of ARO-ANG3 was observed in healthy participants.
• Significant reductions in ANGPTL3, triglycerides, and non-HDL-C were observed with ARO-ANG3 treatment, particularly at higher doses.

Conclusions:

• ARO-ANG3 demonstrated a favorable safety profile and effective reduction of key lipid parameters.
• These findings support ANGPTL3 as a viable therapeutic target for the management of dyslipidemia and ASCVD.
• Further investigation of ARO-ANG3 in larger clinical trials is warranted.